Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia

Acta Psychiatrica Scandinavica

Volumn 130, Issue 4, 2014, Pages 290-299

  Fervaha, G ^a,b   Foussias, G ^a,b,c   Agid, O ^a,b,c   Remington, G ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amotivation; Avolition apathy; Functional outcome; Negative symptoms; Neurocognition; Schizophrenia

Indexed keywords

OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; BARNES AKATHISIA SCALE; BODY MASS; CALGARY DEPRESSION SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; MACARTHUR COMPETENCE ASSESSMENT; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT OUTCOME; VERBAL MEMORY; WORKING MEMORY; APATHY; LONGITUDINAL STUDY; MIDDLE AGED; MOTIVATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX;

ADULT; APATHY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTIVATION; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84907987356     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12289     Document Type: Article

References (63)

1. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry 2005;50:892-900.
2. Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-436.
3. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087.
4. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162:495-506.
5. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008;165:978-987.
6. Perlick DA, Rosenheck RA, Kaczynski R, Bingham S, Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr Res 2008;99:192-199.
7. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012;137:147-150.
8. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330.
9. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006;163:418-425.
10. Rosenheck R, Leslie D, Keefe R et al. Barriers to employment for people with schizophrenia. Am J Psychiatry 2006;163:411-417.
11. Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry 2012;27:432-436.
12. Ueoka Y, Tomotake M, Tanaka T et al. Quality of life and cognitive dysfunction in people with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:53-59.
13. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 2005;31:167-174.
14. Fervaha G, Remington G. Validation of an abbreviated quality of life scale for schizophrenia. Eur Neuropsychopharmacol 2013;23:1072-1077.
15. Fervaha G, Foussias G, Siddiqui I, Agid O, Remington G. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophr Res 2014;154:89-92.
16. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006;32:238-245.
17. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull 2010;36:359-369.
18. Messinger JW, Tremeau F, Antonius D et al. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 2011;31:161-168.
19. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998;155:1196-1201.
20. Pogue-Geile MF, Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull 1985;11:427-439.
21. Foussias G, Mann S, Zakzanis KK, van Reekum R, Agid O, Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr Res 2011;132:24-27.
22. Konstantakopoulos G, Ploumpidis D, Oulis P et al. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr Res 2011;133:193-198.
23. Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res 2013;210:665-668.
24. Kiang M, Christensen BK, Remington G, Kapur S. Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr Res 2003;63:79-88.
25. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry 2013;170:165-172.
26. Green MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry 2012;69:1216-1224.
27. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:280-287.
28. Stroup TS, McEvoy JP, Swartz MS et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31.
29. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
30. First MB. User's guide for the structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version. Washington, DC: Amer Psychiatric Pub Inc, 1997.
31. Appelbaum PS, Grisso T. MacArthur competence assessment tool for clinical research (MacCAT-CR). Sarasota, FL: Professional Resource Press, 2001.
32. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398.
33. Leifker FR, Patterson TL, Heaton RK, Harvey PD. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr Bull 2011;37:334-343.
34. Harvey PD, Sabbag S, Prestia D, Durand D, Twamley EW, Patterson TL. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J Psychiatr Res 2012;46:1546-1552.
35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
36. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546.
37. Keefe RS, Mohs RC, Bilder RM et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003;29:45-55.
38. Keefe RS, Bilder RM, Harvey PD et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31:2033-2046.
39. Green MF, Nuechterlein KH, Gold JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301-307.
40. Nuechterlein KH, Green MF, Kern RS et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-213.
41. Guy W. ECDEU assessment manual for psychopharmacology-revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare, 1976.
42. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251.
43. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183.
44. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-19.
45. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
46. McEvoy JP, Apperson LJ, Appelbaum PS et al. Insight in schizophrenia. Its relationship to acute psychopathology. J Nerv Ment Dis 1989;177:43-47.
47. Kaiser HF. A second generation little jiffy. Psychometrika 1970;35:401-415.
48. Bartlett MS. Tests of significance in factor analysis. Br J Stat Psychol 1950;3:77-85.
49. Fisher RA. Frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population. Biometrika 1915;10:507-521.
50. Fisher RA. On the "Probable Error" of a Coefficient of Correlation Deduced from a Small Sample. Metron 1921;1:3-32.
51. Evensen J, Rossberg JI, Barder H et al. Apathy in first episode psychosis patients: a ten year longitudinal follow-up study. Schizophr Res 2012;136:19-24.
52. Faerden A, Friis S, Agartz I et al. Apathy and functioning in first-episode psychosis. Psychiatr Serv 2009;60:1495-1503.
53. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-162.
54. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res 2013;47:718-725.
55. Harvey PD, Koren D, Reichenberg A, Bowie CR. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 2006;32:250-258.
56. Bell MD, Mishara AL. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments Schizophr Res 2006;81:17-27.
57. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res 2009;113:189-199.
58. Gard DE, Fisher M, Garrett C, Genevsky A, Vinogradov S. Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr Res 2009;115:74-81.
59. Nakagami E, Xie B, Hoe M, Brekke JS. Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr Res 2008;105:95-104.
60. Fervaha G, Agid O, Foussias G, Remington G. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study. Schizophr Res 2014;152:317-318.
61. Fervaha G, Foussias G, Agid O, Remington G. Neural substrates of effort computation in schizophrenia. Neurosci Biobehav Rev 2013;37:2649-2665.
62. Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res 2013;150:58-63.
63. Sanchez P, Pena J, Bengoetxea E et al. Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial. Schizophr Bull 2014;40:707-715.